文献速递浆细胞疾病

不同骨髓细胞群中的IKAROS表达作为来那度胺-地塞米松治疗多发性骨髓瘤结局的候选生物标志物

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
PubMed 文献 · Am J Hematol · 2017-02-01

研究分析了44例接受来那度胺-地塞米松治疗的多发性骨髓瘤患者全骨髓样本中6个免疫调节药物靶基因的表达,发现CRBN、IKZF1、IRF4、MCT-1和CD147表达与疗效显著相关。多色流式细胞术显示,总骨髓单个核细胞、CD19+B细胞、CD3+CD8+T细胞及单核细胞中高IKAROS蛋白水平与更优总生存相关,而骨髓瘤细胞中IKAROS蛋白表达无预测价值。

要点

  • 全骨髓中CRBN、IKZF1、IRF4、MCT-1和CD147表达与来那度胺-地塞米松疗效显著相关,IKZF3不相关。
  • 总骨髓单个核细胞、CD19+B细胞、CD3+CD8+T细胞及单核细胞中高IKAROS蛋白与更优总生存相关。
  • 骨髓瘤细胞中IKAROS蛋白表达对总生存无预测价值。

核心结论

  • 数据证实免疫细胞在免疫调节药物临床活性中的核心作用,并为前瞻性分析不同细胞群中IKAROS蛋白水平作为免疫调节药物潜在生物标志物奠定基础。

研究设计与样本

  • 研究分析了44例接受来那度胺-地塞米松治疗的多发性骨髓瘤患者全骨髓样本中6个免疫调节药物靶基因的表达。

主要发现

  • 全骨髓中CRBN表达与疗效显著相关(R=0.30,P=.05)。
  • 全骨髓中IKZF1表达与疗效显著相关(R=0.31,P=.04)。
  • 全骨髓中IRF4表达与疗效显著相关(R=0.38,P=.01)。
  • 全骨髓中MCT-1表达与疗效显著相关(R=0.30,P=.05)。
  • 全骨髓中CD147表达与疗效显著相关(R=0.38,P=.01),而IKZF3不相关(R=-0.15,P=.34)。

关键数值与推荐

  • 总骨髓单个核细胞中高IKAROS蛋白水平与更优总生存相关(中位OS 83.4 vs. 32.2个月,P=.02)。
  • CD19+B细胞中高IKAROS蛋白水平与更优总生存相关(中位OS 71.1 vs. 32.2个月,P=.05)。
  • CD3+CD8+T细胞中高IKAROS蛋白水平与更优总生存相关(中位OS 83.4 vs 19.0个月,P=.008)。
  • 单核细胞中高IKAROS蛋白水平与更优总生存相关(中位OS 53.9 vs 18.0个月,P=.009)。
  • 骨髓瘤细胞中IKAROS蛋白表达对总生存无预测价值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory drugs (IMiDs) are a cornerstone in the treatment of multiple myeloma (MM), but specific markers to predict outcome are still missing. Recent work pointed to a prognostic role for IMiD target genes (e.g. CRBN). Moreover, indirect activity of IMiDs on immune cells correlated with outcome, raising the possibility that cell populations in the bone marrow (BM) microenvironment could serve as biomarkers. We therefore analysed gene expression levels of six IMiD target genes in whole BM samples of 44 myeloma patients treated with lenalidomide-dexamethasone. Expression of CRBN (R = 0.30, P = .05), IKZF1 (R = 0.31, P = .04), IRF4 (R = 0.38, P = .01), MCT-1 (R = 0.30, P = .05), and CD147 (R = 0.38, P = .01), but not IKZF3 (R = -0.15, P = .34), was significantly associated with response. Interestingly, IKZF1 expression was elevated in BM environmental cells and thus selected for further investigation by multicolor flow cytometry. High IKAROS protein levels in total BM mononuclear cells (median OS 83.4 vs. 32.2 months, P = .02), CD19+ B cells (median OS 71.1 vs. 32.2 months, P = .05), CD3+ CD8+ T cells (median OS 83.4 vs 19.0 months, P = .008) as well as monocytes (median OS 53.9 vs 18.0 months, P = .009) were associated with superior overall survival (OS). In contrast, IKAROS protein expression in MM cells was not predictive for OS. Our data therefore corroborate the central role of immune cells for the clinical activity of IMiDs and built the groundwork for prospective analysis of IKAROS protein levels in distinct cell populations as a potential biomarker for IMiD based therapies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Bolomsky A, Hübl W, Spada S, et al. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma. Am J Hematol. 2017. PMID: 28052520. doi:10.1002/ajh.24634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。